新闻简报：WEX 在 IASP 世界大会上发表关于其先导化合物 Halneuron® 止痛的科学海报
不列颠哥伦比亚省温哥华（2022 年 9 月 22 日）——威克斯药业有限公司（“WEX”或“公司”）
新闻简报：WEX 在 IASP 世界疼痛大会上宣布了关于Halneuron®（河豚毒素“TTX”）
不列颠哥伦比亚省温哥华（2022 年 8 月 31 日）——威克斯药业有限公司（“WEX”或“公司”）
News Brief: Wex Pharmaceuticals Inc. Announces Abstract And Poster Presentation At The IASP World Congress On Pain On The Lead Compound, TTX (Halneuron )®
Vancouver, BC (August 31, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that a poster presentation on the Company’s lead drug candidate Halneuron was accepted for presentation at the International Association for the Study of Pain (IASP)
News Brief: Publication of Two Papers Using Halneuron®
Vancouver, BC (April 30, 2021) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for chronic pain, announced the publication of two clinical studies in a special issue of the Toxins Journal, Tetrodotoxin (TTX) as a Therapeutic Agent.
新闻简报：发表了两篇使用 Halneuron®的论文
不列颠哥伦比亚省温哥华（2021 年 4 月 30 日）——威克斯药业有限公司（“WEX”或“公司”）…
NEWS BRIEF: WEX Successfully Completes Cardiac Safety Clinic Trial of Halneuron™
Vancouver, BC (March 30, 2018) ‐ WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing HalneuronTM (Tetrodotoxin or TTX) for pain, today announced the successful completion of the thorough electrocardiogram (“ECG”) study of Halneuron conducted in healthy volunteers.